GTT to Present at August 2017 Investor Conferences

MCLEAN, Va.--(BUSINESS WIRE)-- GTT Communications, Inc. (NYSE: GTT), the leading global cloud networking provider to multinational clients, will present at the following investor conferences in August:

• On August 7, Rick Calder, GTT CEO, will present at The Pacific Crest 19th Annual Global Technology Leadership Forum in Vail, Colorado, at 9:30 a.m. MT and meet with investors.
• On August 8, Mr. Calder will present at the 3rd Annual Cowen Communications Infrastructure Summit in Boulder, Colorado, at 10:55 a.m. MT and meet with investors.
• On August 8, Mike Sicoli, GTT CFO, and Chris McKee, general counsel and EVP, Corporate Development, will present at the Oppenheimer 20th Annual Technology, Internet & Communications Conference in Boston, Massachusetts, at 3:05 p.m. ET and meet with investors.

A copy of the company’s latest investor presentation is available on the company’s website.

About GTT

GTT provides multinationals with a better way to reach the cloud through its suite of cloud networking services, including wide area networking, internet, managed services and voice services. The company’s Tier 1 IP network, ranked in the top five worldwide, connects clients to any location in the world and any application in the cloud. GTT delivers an outstanding client experience by living its core values of simplicity, speed and agility. For more information on how GTT is redefining global communications, please visit www.gtt.net.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170801005366/en/

GTT Investor Relations:
LHA
Jody Burfening/Carolyn Capaccio, +1-212-838-3777
[email protected]
or
GTT Media Inquiries:
GTT
Randall Slack, +1-646-254-6905
[email protected]

Source: GTT Communications, Inc.

You May Also Be Interested In

• TD Cowen Upgrades Sezzle Inc (SEZL) to Buy 'on more compelling valuation'
• BASF Agricultural Solutions invests in new Climate Center at its headquarters to strengthen research capabilities
• Senhwa's CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research